GSK’s ViiV Healthcare Confirms Staying Power of Long-Acting HIV Treatment Cabenuva in Adolescents

In the Mocha study, 94.4% of adolescents aged 12–18 maintained viral suppression after switching from daily oral HIV therapy to Cabenuva injections every two months. More than 97% of participants preferred the long-acting regimen, with 100% favoring it at Week 96, highlighting its convenience and impact on adherence.